每经记者:陈星每经编辑:张海妮近期,港股上市公司兆科眼科(HK06622,股价1.880港元,市值10.27亿港元)发布2024年业绩。报告期内,公司取得收入6932.4万元,同比增长268.6%,净亏损同比收窄38.3%,在手现金达到11.2亿元。相较2024年的业绩表现,投资者更关心兆科眼科的核心管线之一“低浓度阿托品滴眼液”何时能够获批上市。今年1月,兆科眼科公告称,国家药品监督管理局已受理...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.